S&P 500   3,273.97 (-1.37%)
DOW   27,084.00 (-2.07%)
QQQ   265.15 (-0.64%)
AAPL   108.67 (+1.71%)
MSFT   200.69 (+0.15%)
FB   247.57 (-1.96%)
GOOGL   1,422.33 (-1.98%)
AMZN   2,911.29 (-1.48%)
NVDA   495.96 (+1.72%)
TSLA   445.41 (+0.74%)
BABA   272.70 (+0.11%)
CGC   15.71 (-3.97%)
GE   6.32 (-8.14%)
MU   48.78 (-3.86%)
AMD   77.33 (+3.20%)
T   28.50 (-1.49%)
F   6.85 (-5.26%)
ACB   6.35 (-2.76%)
GILD   63.71 (-2.06%)
NFLX   481.81 (+2.52%)
DIS   124.85 (-2.94%)
BAC   24.36 (-3.37%)
BA   156.68 (-2.77%)
S&P 500   3,273.97 (-1.37%)
DOW   27,084.00 (-2.07%)
QQQ   265.15 (-0.64%)
AAPL   108.67 (+1.71%)
MSFT   200.69 (+0.15%)
FB   247.57 (-1.96%)
GOOGL   1,422.33 (-1.98%)
AMZN   2,911.29 (-1.48%)
NVDA   495.96 (+1.72%)
TSLA   445.41 (+0.74%)
BABA   272.70 (+0.11%)
CGC   15.71 (-3.97%)
GE   6.32 (-8.14%)
MU   48.78 (-3.86%)
AMD   77.33 (+3.20%)
T   28.50 (-1.49%)
F   6.85 (-5.26%)
ACB   6.35 (-2.76%)
GILD   63.71 (-2.06%)
NFLX   481.81 (+2.52%)
DIS   124.85 (-2.94%)
BAC   24.36 (-3.37%)
BA   156.68 (-2.77%)
S&P 500   3,273.97 (-1.37%)
DOW   27,084.00 (-2.07%)
QQQ   265.15 (-0.64%)
AAPL   108.67 (+1.71%)
MSFT   200.69 (+0.15%)
FB   247.57 (-1.96%)
GOOGL   1,422.33 (-1.98%)
AMZN   2,911.29 (-1.48%)
NVDA   495.96 (+1.72%)
TSLA   445.41 (+0.74%)
BABA   272.70 (+0.11%)
CGC   15.71 (-3.97%)
GE   6.32 (-8.14%)
MU   48.78 (-3.86%)
AMD   77.33 (+3.20%)
T   28.50 (-1.49%)
F   6.85 (-5.26%)
ACB   6.35 (-2.76%)
GILD   63.71 (-2.06%)
NFLX   481.81 (+2.52%)
DIS   124.85 (-2.94%)
BAC   24.36 (-3.37%)
BA   156.68 (-2.77%)
S&P 500   3,273.97 (-1.37%)
DOW   27,084.00 (-2.07%)
QQQ   265.15 (-0.64%)
AAPL   108.67 (+1.71%)
MSFT   200.69 (+0.15%)
FB   247.57 (-1.96%)
GOOGL   1,422.33 (-1.98%)
AMZN   2,911.29 (-1.48%)
NVDA   495.96 (+1.72%)
TSLA   445.41 (+0.74%)
BABA   272.70 (+0.11%)
CGC   15.71 (-3.97%)
GE   6.32 (-8.14%)
MU   48.78 (-3.86%)
AMD   77.33 (+3.20%)
T   28.50 (-1.49%)
F   6.85 (-5.26%)
ACB   6.35 (-2.76%)
GILD   63.71 (-2.06%)
NFLX   481.81 (+2.52%)
DIS   124.85 (-2.94%)
BAC   24.36 (-3.37%)
BA   156.68 (-2.77%)
Log in
NASDAQ:ALDX

Aldeyra Therapeutics Stock Forecast, Price & News

$6.95
-0.48 (-6.46 %)
(As of 09/21/2020 03:34 PM ET)
Add
Compare
Today's Range
$6.79
Now: $6.95
$7.29
50-Day Range
$5.85
MA: $6.74
$7.46
52-Week Range
$1.48
Now: $6.95
$8.05
Volume23,974 shs
Average Volume740,020 shs
Market Capitalization$268.50 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Read More
Aldeyra Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.17 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-60,830,000.00

Miscellaneous

Employees15
Market Cap$268.50 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$6.95
-0.48 (-6.46 %)
(As of 09/21/2020 03:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

How has Aldeyra Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALDX stock has increased by 144.8% and is now trading at $6.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aldeyra Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aldeyra Therapeutics
.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aldeyra Therapeutics
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.09.
View Aldeyra Therapeutics' earnings history
.

What price target have analysts set for ALDX?

5 brokers have issued 12 month price targets for Aldeyra Therapeutics' stock. Their forecasts range from $15.00 to $33.00. On average, they anticipate Aldeyra Therapeutics' share price to reach $25.60 in the next twelve months. This suggests a possible upside of 274.8% from the stock's current price.
View analysts' price targets for Aldeyra Therapeutics
.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 817,300 shares, an increase of 30.8% from the August 15th total of 624,700 shares. Based on an average trading volume of 1,120,000 shares, the days-to-cover ratio is currently 0.7 days.
View Aldeyra Therapeutics' Short Interest
.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), KushCo (KSHB), Sorrento Therapeutics (SRNE), AEterna Zentaris (AEZS), BioNano Genomics (BNGO), OrganiGram (OGI), Pennsylvania R.E.I.T. (PEI) and Cannabics Pharmaceuticals (CNBX).

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer and Director (Age 48)
  • Joshua Reed, Chief Financial Officer (Age 47)
  • David McMullin, Chief Commercial Officer (Age 45)
  • James A. Gow, M.D., Senior Vice President of Clinical Development (Age 53)
  • Stephen G. Machatha, Ph.D., Senior Vice President, Technical Operation (Age 43)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Prosight Management LP (5.44%), FMR LLC (2.05%), FMR LLC (1.58%), Jacobs Levy Equity Management Inc. (0.79%), Woodstock Corp (0.50%) and Schonfeld Strategic Advisors LLC (0.36%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends for Aldeyra Therapeutics
.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Prosight Management LP, Bank of New York Mellon Corp, Algert Global LLC, and Mesirow Financial Investment Management Inc..
View insider buying and selling activity for Aldeyra Therapeutics
.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Schonfeld Strategic Advisors LLC, Jane Street Group LLC, Stifel Financial Corp, Two Sigma Advisers LP, Russell Investments Group Ltd., Quantitative Systematic Strategies LLC, and State of Wisconsin Investment Board. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Perceptive Advisors Llc, Richard Douglas, and Todd C Brady.
View insider buying and selling activity for Aldeyra Therapeutics
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $6.83.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $263.86 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis. Aldeyra Therapeutics employs 15 workers across the globe.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is www.ampliphibio.com.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.